This Week in Virology TWiV 1162: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin informs us about “walking pneumonia”, the phase of the polio supplemental immunization campaign in Gaza, mpox circulation, the Marburg virus outbreak in Rwanda, the beginning of influenza season, before reviewing the recent statistics on SARS-CoV-2 infection, the WasterwaterScan dashboard, contrasting public health concerns between the US and the UK, if mRNA boosters affect mucosal immunity against SARS-CoV-2 infection, where to find PEMGARDA, a reminder of how and when to use steroids to treat COVID-19, if antiviral therapy prevents long COVID and viral sequalae in healthy young marines.
Subscribe (free): Apple Podcasts, RSS, emailBecome a patron of TWiV!
Links for this episode- Mycoplasma pneumoniae infections increasing (CDC)
- Polio vaccination campaign restarts (Reuters)
- North Gaza polio campaign postponed (Reuters)
- 1St clade 1b mpox in UK (GOV.UK)
- UK imports mpox (CIDRAP)
- Clinical trial of MVA-BN for children (Bavarian-Nordic)
- How to stop Marburg virus (Rwanda Biomedical Centre)
- Marburg Virus fact sheet (Rwanda Biomedical Centre)
- Laboratory confirmed influenza associated hospitalizations 2010-2023 (CDC)
- Influenza weekly surveillance report: cliff notes (CDC FluView)
- Mucosal nirsevimab levels in breakthrough bronchiolitis (LANCET Infectious Diseases)
- RSV NETwork (CDC RSV)
- Respiratory virus activity (CDC Respiratory Illnesses)
- COVID-19 deaths (CDC)
- COVID-19 national and regional trends (CDC)
- Waste water scan for 11 pathogens (WastewaterSCan)
- UK public health data tracker (UKHSA)
- COVID-19 variant tracker (CDC)
- SARS-CoV-2 genomes galore (Nextstrain)
- Repeat COVID-19 mRNA vaccination contributes to mucosa immunity (Science Translational Medicine)
- XBB.1.5 mRNA booster vaccination limited mucosal immunity (Science Translational Medicine)
- I repeat: COVID mRNA booster vaccinations suboptimal respiratory mucosal immunity (Science Translational Medicie)
- Facial Palsy after COVID-19 vaccination? (Emerging Infectious Diseases)
- New preventive COVID-19 agent (ISDA)
- IDSA Guidelines on the Treatment and Management of Patients with COVID-19 (IDSA)
- Where to get pemgarda (Pemgarda)
- EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD)
- Fusion center near you….if in NY (Prime Fusions)
- CDC Quarantine guidelines (CDC)
- NIH COVID-19 treatment guidelines (NIH)
- Infectious Disease Society guidelines for treatment and management (ID Society)
- Viral and symptom rebound following monoclonal antibody therapy (JID)
- Drug interaction checker (University of Liverpool)
- Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID (Scientific Reports)
- Molnupiravir safety and efficacy (JMV)
- Convalescent plasma recommendation for immunocompromised (ID Society)
- Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo (JAMA Network Open)
- What to do when sick with a respiratory virus (CDC)
- When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC)
- Managing healthcare staffing shortages (CDC)
- Steroids, dexamethasone at the right time (OFID)
- Anticoagulation guidelines (hematology.org)
- Clinical and functional assessment of SARS-CoV-2 sequelae among young marines
- (LANCET: Regional Health Americas)
- Letters read on TWiV 1162
- Dr. Griffin’s COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv